E Fund Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

E Fund Management’s Portfolio CRNX Stock Details CRNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	$291K	Buy	10,131 +586	+6%	+$18.1K	0.01%	312
2025 Q1	$320K	Buy	9,545 +3,770	+65%	+$141K	0.02%	299
2024 Q4	$295K	Sell	5,775 -487	-8%	-$27.2K	0.01%	318
2024 Q3	$320K	Sell	6,262 -551	-8%	-$28.4K	0.02%	248
2024 Q2	$305K	Sell	6,813 -3,435	-34%	-$159K	0.02%	229
2024 Q1	$480K	Sell	10,248 -2,821	-22%	-$110K	0.03%	162
2023 Q4	$465K	Buy	13,069 +2,914	+29%	+$89.4K	0.03%	176
2023 Q3	$302K	Buy	+10,155	New	+$209K	0.02%	207

Other funds holding CRNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

E Fund Management's CRNX Position: Q2 2025 in Review

E Fund Management increased its Crinetics Pharmaceuticals (CRNX) stake by 6.1% in Q2 2025, buying an estimated $18.1K and bringing the position to 10,131 shares worth $291K. The position accounts for 0.01% of the portfolio, ranked #312.

E Fund Management first reported a position in CRNX in Q3 2023 and has held it in 8 quarters since. The position peaked at $480K in Q1 2024. 222 funds tracked by Wall St. Rank hold CRNX as of Q2 2025.

E Fund Management held 10,131 shares of Crinetics Pharmaceuticals worth $291K as of Q2 2025.
E Fund Management bought 586 Crinetics Pharmaceuticals shares in Q2 2025, an estimated $18.1K.
Crinetics Pharmaceuticals made up 0.01% of E Fund Management's portfolio in Q2 2025, its #312 holding.
E Fund Management first reported a position in Crinetics Pharmaceuticals in Q3 2023 and has held it in 8 quarters since.
E Fund Management's Crinetics Pharmaceuticals position peaked at $480K in Q1 2024.
222 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2025.

Based on E Fund Management's 13F filing for Q2 2025, filed 15 Aug 2025.